Related Experiment Video
Updated: Dec 20, 2025
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?
Michelle N Rheault1, William E Smoyer2
1Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, USA.
Insights
Early treatment with angiotensin-converting enzyme inhibitors (ACE inhibitors) shows long-term safety and clinical benefit in children with Alport syndrome. This approach helps slow albuminuria progression and estimated glomerular filtration rate decline.
Area of Science:
- Pediatric Nephrology
- Clinical Trials
- Genetics
Background:
- Alport syndrome is a genetic kidney disorder characterized by progressive loss of kidney function.
- Early intervention strategies are crucial to slow disease progression in pediatric patients.
- Angiotensin-converting enzyme inhibitors (ACE inhibitors) are a potential therapeutic class.
Purpose of the Study:
- To evaluate the long-term safety and clinical efficacy of ramipril compared to placebo in children with early-stage Alport syndrome.
- To assess the impact of early ACE inhibitor treatment on key markers of kidney disease progression.
Main Methods:
- The EARLY PRO-TECT trial was a randomized, placebo-controlled study.
- Participants were children diagnosed with early-stage Alport syndrome.
- Treatment involved ramipril or a placebo.
Main Results:
- The trial, though under-enrolled, provided supportive evidence for the safety of ramipril.
- Ramipril demonstrated a clinical benefit in slowing the progression of albuminuria.
- Early ACE inhibitor treatment also showed a positive effect on estimated glomerular filtration rate decline.
Conclusions:
- Early treatment with ACE inhibitors, specifically ramipril, is safe for children with Alport syndrome.
- This therapeutic approach offers a clinical benefit by slowing kidney function decline and reducing albuminuria.
- The findings support the use of ACE inhibitors as a management strategy in pediatric Alport syndrome.
Abstract:
Gross et al. present results of the EARLY PRO-TECT trial, a randomized controlled trial of ramipril versus placebo in children with early-stage Alport syndrome. Although under-enrolled and not a positive trial in the traditional sense, EARLY PRO-TECT does provide strong supportive evidence for both long-term safety and a clinical benefit of early treatment with angiotensin-converting enzyme inhibitors in slowing the progression of both albuminuria and estimated glomerular filtration rate decline in children with Alport syndrome.
More Related Videos
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...